Publication

8-Hydroxy-2-deoxyguanosine prevents plaque formation and inhibits vascular smooth muscle cell activation through Rac1 inactivation

Downloadable Content

Persistent URL
Last modified
  • 03/03/2025
Type of Material
Authors
    Joo Young Huh, Ewha Womans UniversityDongju Son, Emory UniversityYoonji Lee, Ewha Womans UniversityJunghyun Lee, Ewha Womans UniversityBoyeon Kim, Ewha Womans UniversityHwan Myung Lee, Hoseo UniversityHanjoong Jo, Emory UniversitySun Choi, Ewha Womans UniversityHunjoo Ha, Ewha Womans UniversityMyung-Hee Chung, Sungkyunkwan University
Language
  • English
Date
  • 2012-07-01
Publisher
  • Elsevier
Publication Version
Copyright Statement
  • © 2012 Elsevier Inc.
Final Published Version (URL)
Title of Journal or Parent Work
ISSN
  • 0891-5849
Volume
  • 53
Issue
  • 1
Start Page
  • 109
End Page
  • 121
Grant/Funding Information
  • Joo Young Huh, Yoonji Lee, Junghyun Lee, and Boyeon Kim were supported by the Brain Korea 21 Project.
  • This work was supported, in part, by the Ministry of Education, Science, and Technology (MEST, 314-2008-1-E00056 and 2011-0028885) and the WCU project (R31-2008-000-10010-0).
Supplemental Material (URL)
Abstract
  • 8-Hydroxy-2-deoxyguanosine (8-OHdG), a marker of oxidative stress, has been recently rediscovered to inhibit Rac1 in neutrophils and macrophages, thereby inhibiting Rac1-linked functions of these cells, including reactive oxygen species production through NADPH oxidase activation, phagocytosis, chemotaxis, and cytokine release. In vascular smooth muscle cells (VSMCs), reactive oxygen species also induce abnormal proliferation and migration leading to progression of atherosclerosis. Based upon the involvement of reactive oxygen species in phagocytic cells and VSMCs during the atherosclerotic process, we hypothesized that 8-OHdG could have antiatherosclerotic action and tested this hypothesis in an experimentally induced atherosclerosis in mice. Partially ligated ApoE knockout mice, a more physiologically relevant model of low and oscillatory flow, developed an advanced lesion in 2 weeks, and orally administered 8-OHdG significantly reduced plaque formation along with reduced superoxide formation, monocyte/macrophage infiltration, and extracellular matrix (ECM) accumulation. The effects of 8-OHdG observed in primary VSMCs were consistent with the in vivo effects of 8-OHdG and were inhibitory to angiotensin II or platelet-derived growth factor-induced production of reactive oxygen species, proliferation, migration, and ECM production. Also, angiotensin II-induced Rac1 activity in VSMCs was significantly inhibited by 8-OHdG, and transfection of constitutively active Rac1 reversed the inhibitory effect of 8-OHdG on VSMC activation. Molecular docking study showed that 8-OHdG stabilizes Rac1-GEF complex, indicating the physical contact of 8-OHdG with Rac1. These findings highly suggest that the antiatherosclerotic effect of 8-OHdG is mediated by inhibition of Rac1 activity. In conclusion, our results show a novel action of orally active 8-OHdG in suppressing atherosclerotic plaque formation in vivo and VSMC activation in vitro through inhibition of Rac1, which emphasizes a new therapeutic avenue to benefit atherosclerosis.
Author Notes
Keywords
Research Categories
  • Health Sciences, Medicine and Surgery
  • Biology, Molecular

Tools

Relations

In Collection:

Items